NeoMatrix has received competitive funding from the Armed Forces Institute of Regenerative Medicine (AFIRM), the Joint Warfighter Medical Research Program (JWMRP), and the Military Burn Research Program (MBRP) to develop our novel medicine peptides. To date, NeoMatrix has received over $12M in non-dilutive funding. As a result of this funding, NMT-cP12 is Phase 2-ready and NMT-cNP8 is funded through IND-enabling studies.
We are interested in exploring investments and/or strategic collaborations with pharma partners whose capability and expertise will supplement ours in advancing our products through the clinic and to the market.
About Our Award Funding
Our work was/is supported by (i) the Assistant Secretary of Defense for Health Affairs, through the Defense Medical Research and Development Program (DMRDP) under Award Number W81XWH-20-1-0874, (ii) the U.S. Army Medical Research and Development Command (USAMRDC), through the Congressionally Directed Medical Research Programs (CDMRP) via the Joint Warfighter Research Program (JWMRP) under Award Number W81XWH-15-C-0043 and W81XWH-14-1-0100, and (iii) the U.S. Army Medical Research and Development Command (USAMRDC), through the Military Burn Research Program (MBRP) under Award Number W81XWH-18-2-0059 and W81XWH-17-2-0062.
The views expressed on this website are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.